SCHEMBL24429999

SCHEMBL24429999

CC(C)(C)c1ccc(N2C(=O)C=C(Nc3cc(F)c(O)c(F)c3)C2=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ MAPT P10636 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ XBP1 P17861 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ CA9 Q16790 3/20 0.35
▸ CA12 O43570 2/20 0.35
▸ CA1 P00915 2/20 0.35
▸ RAPGEF3 O95398 2/20 0.33
▸ RAPGEF4 Q8WZA2 2/20 0.33
▸ TP53 P04637 2/20 0.33
▸ CA2 P00918 1/20 0.32
▸ HSD17B3 P37058 1/20 0.32
▸ EPHX2 P34913 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26205901 0.89 KMT2A (0.48) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL24430081 0.89 MEN1 (0.48) KMT2AMEN1KDM4EALDH1A1CA9
SCHEMBL24430113 0.87 MEN1 (0.54) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL24430074 0.86 MEN1 (0.50) KMT2AMEN1KDM4EALDH1A1NPC1
SCHEMBL24430026 0.86 KMT2A (0.52) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL24430002 0.84 MEN1 (0.48) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL24430114 0.84 MEN1 (0.68) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL24430013 0.84 MEN1 (0.49) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL24430078 0.83 MEN1 (0.50) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL24430116 0.83 ALDH1A1 (0.53) KMT2AMEN1KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339860-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease SOUTHERN RES INST (US) 2023-10-26 — — US disclosed
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease Southern Reserach Institute (US) 2023-09-12 — — US disclosed
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease Southern Reserach Institute (US) 2023-09-12 — — US disclosed
WO-2022109067-A1 COMPOUNDS FOR THE TREATMENT OF ACUTE AND CHRONIC KIDNEY DISEASE SOUTHERN RESEARCH INSTITUTE (US) 2022-05-27 — — WO disclosed
WO-2022109066-A1 COMPOUNDS FOR THE TREATMENT OF ACUTE AND CHRONIC KIDNEY DISEASE SOUTHERN RESEARCH INSTITUTE (US) 2022-05-27 — — WO disclosed
US-20220153695-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2022-05-19 — — US disclosed
US-20220153702-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease UAB RESEARCH FOUNDATION 2022-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153695-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease HMOX1, GLS, HMOX2 KMT2A 2088/4885MEN1 4171/4885KDM4E 960/4885
US-20220153702-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease HMOX1, HMOX2, GLS KMT2A 2904/4885MEN1 4651/4885KDM4E 2869/4885
US-20230339860-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease HMOX1, HMOX2, GLS KMT2A 2904/4885MEN1 4651/4885KDM4E 2869/4885
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease HMOX1, GLS, HMOX2 KMT2A 2088/4885MEN1 4171/4885KDM4E 960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback